Manjit Kaur

Manjit Kaur

Auto-generated profile, based on publicly available information

Manjit Kaur

Department of Dermatology, The Ohio State University Wexner Medical Center, Columbus, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2024 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
CSConnie R. Shi
Connie R. Shi
AFAlana L. Ferreira
Alana L. Ferreira
MKManjit Kaur
Manjit Kaur
DXDavid Xiang
David Xiang
JCJean Caputo
Jean Caputo
EBEmily Baumrin
Emily Baumrin
Cutaneous chronic graft-versus-host disease (cGVHD) is associated with morbidity, mortality, and impaired quality of life after hematopoietic stem cell transplantation. The clinical features of cutaneous cGVHD are heterogeneous but can be broadly classified into nonsclerotic or sclerotic presentations. This review provides an overview of clinical presentation, diagnosis and differential diagnosis, grading, and treatment of cutaneous cGVHD. Particular attention is given to cutaneous cGVHD in skin of color, which can have unique features and is generally underrepresented in the literature leading to delays in diagnosis. Finally, an overview of long-term skin care for patients with cutaneous cGVHD is provided in order to support patients from a dermatologic perspective as they recover from cGVHD. Multidisciplinary care with frequent communication between transplant specialists and dermatologists is critical to effectively managing cutaneous cGVHD.

31 July 2025 in International Wound Journal
Verified
Journal Article
Open access
MKManjit Kaur
Manjit Kaur
MDMichael J. Diaz
Michael J. Diaz
MAMichelle Anthony
Michelle Anthony
DJDana Jolley
Dana Jolley
ASAnna H. Schildmeyer
Anna H. Schildmeyer
BKBenjamin H. Kaffenberger
Benjamin H. Kaffenberger
Pyoderma gangrenosum (PG) is a neutrophilic dermatosis associated with significant morbidity and mortality, with no consensus treatment to date. To review all clinical trials of treatments for PG to synthesise clinical evidence regarding the efficacy and safety of different treatments. After PROSPERO (CRD42023459180) registration, we systematically searched five databases (clinicaltrials.gov, CENTRAL, Embase, PubMed and Scopus) up until 18th May 2024 for PG treatments. Of 10 579 identified articles, 5853 deduplicated abstracts were screened. Twenty studies met the screening criteria after a full text review of 60 articles. We assessed the risk of bias using ROBIN‐I for non‐randomised and ROB‐2 for randomised trials. Two reviewers independently performed article screening and quality assessments. Two reviewers independently extracted and recorded data on study characteristics, participants' demographics, disease characteristics, treatment regimens, and outcomes for the selected studies. A single‐arm meta‐analysis of available RCTs and non‐randomised studies was conducted to analyse the outcomes of different systemic immunomodulators. The primary outcome was the complete healing of PG. Secondary outcomes included rates of recurrence, treatment failure, adverse events and time to complete healing. A total of twenty (20) interventional studies were included in the data synthesis: nine (9) prospective open‐label studies, six (6) prospective cohort studies, three (3) open‐label clinical trials, and two (2) randomised controlled trials evaluating multiple biological, systemic, and topical interventions. On random effects meta‐analysis of systemic therapies including adalimumab, canakinumab, infliximab, chlorambucil, cyclosporine, cyclophosphamide and prednisolone, the pooled proportion of complete healing across 11 studies was 0.59 (95% confidence interval [CI]: 0.41–0.74; Χ2 = 26.66, p < 0.01; I2 = 66%); the pooled proportion of PG recurrence across 6 studies was 0.30 (95% CI: 0.20–0.41; Χ2 = 1.14, p = 0.95; I2 = 0%); the pooled proportion of serious adverse effects from 4 studies was 0.10 (95% CI: 0.05–0.19; Χ2 = 5.01, p = 0.17; I2 = 40%); and the pooled proportion of PG treatment failure across seven studies was 0.36 (95% CI: 0.24–0.49; Χ2 = 12.78, p = 0.03; I2 = 61%). The proportion of complete wound healing varies significantly across treatments and recurrence is common even in a limited follow‐up period. Heterogeneity of study methods and low numbers hamper disease research. There remains a significant unmet need for better outcome measures than just complete healing as well as better treatment options to improve patient outcomes.

18 August 2020 in Egyptian Journal of Radiology and Nuclear Medicine
Verified
Journal Article
Open access
PDF file
SGSaryu Gupta
Saryu Gupta
JMJaswinder Kaur Mohi
Jaswinder Kaur Mohi
PGPuneet Gambhir
Puneet Gambhir
MMManjit Kaur Mohi
Manjit Kaur Mohi
Background The aim of this study is to elucidate the spectrum of commonly encountered anomalies affecting fetal genito-urinary system (GUS) on fetal MRI and examine its utility in providing better morphological information resulting in improved diagnostic accuracy and in detecting additional malformations. The study also aims to highlight the promising role of fetal MRI in the detection and characterization of renal fusion anomalies like the horseshoe kidney or developmental abnormalities such as renal agenesis/ectopia. Results The mean age of study participants was 29years 3years. The gestation age of pregnant mothers ranged from 18 weeks and 1 day to 39 weeks and 0 day. Amniotic fluid was reduced or absent in 41% (N = 13) and normal in 59% (N = 18) of participating mothers. Overall, urinary obstruction was the commonest anomaly encountered (29%) followed by the multicystic dysplastic kidney (MCDK) (22%). Bilateral renal disease was seen in all mothers having features of anhydramnios {B/L MCDK (N = 3), autosomal recessive polycystic kidney disease (ARPKD) (N = 2), posterior urethral valves (PUV) (N = 2), B/L renal agenesis (N = 3), and megacystis (N = 1)}. Fusion anomalies (horseshoe kidney) and rotation anomaly (malrotation) were detected in one case each. Additional extrarenal findings were seen on fetal MRI in 35% (N = 11) cases. Conclusions Fetal MRI improves diagnostic accuracy in anomalies affecting the fetal kidney and genito-urinary systems by better morphological delineation. It has the ability to detect additional extra-renal malformations and perform a more accurate assessment of associated pulmonary hypoplasia. The diffusion-weighted sequence is particularly useful in confirming the diagnosis of renal agenesis/ectopia.

24 March 2025 in International Wound Journal
Verified
Journal Article
Open access
MKManjit Kaur
Manjit Kaur
MAMichelle R. Anthony
Michelle R. Anthony
CYColeman Yamakoshi
Coleman Yamakoshi
ASAnna Schildmeyer
Anna Schildmeyer
TMTeja Mallela
Teja Mallela
BKBenjamin H. Kaffenberger
Benjamin H. Kaffenberger

21 October 2024 in Archives of Dermatological Research
Verified
Journal Article
Closed access
PDF file
MKManjit Kaur
Manjit Kaur
JMJacob McFeeters
Jacob McFeeters
DSDivyaam Satija
Divyaam Satija
JSJacob M. Skeans
Jacob M. Skeans
APAntoinette Pusateri
Antoinette Pusateri
BKBenjamin H. Kaffenberger
Benjamin H. Kaffenberger

9 September 2024 in Pigment International
Verified
Journal Article
Open access
MKManjit Kaur
Manjit Kaur
SMSuresh Kumar Malhotra
Suresh Kumar Malhotra
Background: Vitiligo is a common skin disorder that entails cosmetic disfigurement due to depigmentation and carries a social stigma. Smash grafting is an easy-to-master surgical treatment modality for stable vitiligo that has failed to respond to other treatments. The technique involves procuring a thin skin graft from a donor site, smashing it into the thinnest possible pieces, and grafting the smash onto the dermabraded vitiligo site. Objective: To analyze the efficacy and safety of smash grafting in patients with stable vitiligo. Materials and Methods: Thirty patients underwent smash grafting in stable recalcitrant vitiligo lesions. The patients were randomly placed in groups A and B. Group A received PUVASOL therapy postprocedure, while group B received only sunlight exposure after smash grafting. The patients were followed up every month for 3 months to assess repigmentation of the grafted site compared to the patient’s normal skin color. Results: Repigmentation was noticed at the grafted site starting as early as 3 weeks postprocedure in all the patients, and an increase in pigmentation intensity was observed until the end of the study follow-up. At the end of the 3-month follow-up, 76.66% of the patients had regained 50% or more pigmentation of the involved lesion. Conclusion: Smash grafting provided excellent repigmentation in >75% of patients without any significant complications. It is a simple and effective surgical technique that is underutilized. Furthermore, this procedure is less resource-intensive and easier to master than other surgical techniques for vitiligo.